دورية أكاديمية
أعرض في EDS

B-cell activating factor BAFF as a novel alert marker for the immunological risk stratification after kidney transplantation.

التفاصيل البيبلوغرافية
العنوان: B-cell activating factor BAFF as a novel alert marker for the immunological risk stratification after kidney transplantation.
المؤلفون: Schuster AM; Department of Nephrology, University Hospital Regensburg, Franz-Josef-Strauß-Allee 11, 93053, Regensburg, Germany. antonia-margarete.schuster@ukr.de., Miesgang N; Department of Nephrology, University Hospital Regensburg, Franz-Josef-Strauß-Allee 11, 93053, Regensburg, Germany., Steines L; Department of Nephrology, University Hospital Regensburg, Franz-Josef-Strauß-Allee 11, 93053, Regensburg, Germany., Bach C; Department of Internal Medicine 5, University Hospital Erlangen, Erlangen, Germany., Banas B; Department of Nephrology, University Hospital Regensburg, Franz-Josef-Strauß-Allee 11, 93053, Regensburg, Germany., Bergler T; Department of Nephrology, University Hospital Regensburg, Franz-Josef-Strauß-Allee 11, 93053, Regensburg, Germany.
المصدر: Immunologic research [Immunol Res] 2021 Dec; Vol. 69 (6), pp. 487-495. Date of Electronic Publication: 2021 Aug 10.
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Humana Press Country of Publication: United States NLM ID: 8611087 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1559-0755 (Electronic) Linking ISSN: 0257277X NLM ISO Abbreviation: Immunol Res Subsets: MEDLINE
أسماء مطبوعة: Publication: Totawa Nj : Humana Press
Original Publication: Basel ; New York : S. Karger, [c1986-
مواضيع طبية MeSH: B-Cell Activating Factor*/blood , B-Cell Activating Factor*/immunology , Graft Rejection*/blood , Graft Rejection*/immunology , Kidney Transplantation*, Graft Survival/*immunology, Adult ; Aged ; Biomarkers/blood ; Female ; Follow-Up Studies ; Humans ; Male ; Middle Aged ; Risk Assessment
مستخلص: The B cell activating factor BAFF has gained importance in the context of kidney transplantation due to its role in B cell survival. Studies have shown that BAFF correlates with an increased incidence of antibody-mediated rejection and the development of donor-specific antibodies. In this study, we analyzed a defined cohort of kidney transplant recipients who were treated with standardized immunosuppressive regimens according to their immunological risk profile. The aim was to add BAFF as an awareness marker in the course after transplantation to consider patient's individual immunological risk profile. Included patients were transplanted between 2016 and 2018. Baseline data, graft function, the occurrence of rejection episodes, signs of microvascular infiltration, and DSA kinetics were recorded over 3 years. BAFF levels were determined 14 d, 3 and 12 months post transplantation. Although no difference in graft function could be observed, medium-risk patients showed a clear dynamic in their BAFF levels with low levels shortly after transplantation and an increase in values of 123% over the course of 1 year. Patients with high BAFF values were more susceptible to rejection, especially antibody-mediated rejection and displayed intensified microvascular inflammation; the combination of high BAFF + DSA puts patients at risk. The changing BAFF kinetics of the medium risk group as well as the increased occurrence of rejections at high BAFF values enables BAFF to be seen as an awareness factor. To compensate the changing immunological risk, a switch from a weaker induction therapy to an intensified maintenance therapy is required.
(© 2021. The Author(s).)
References: Am J Transplant. 2012 May;12(5):1157-67. (PMID: 22429309)
Int J Mol Sci. 2020 Jan 25;21(3):. (PMID: 31991734)
Immunol Med. 2020 Mar;43(1):16-35. (PMID: 32107989)
Cytokine Growth Factor Rev. 2013 Jun;24(3):203-15. (PMID: 23684423)
Transplant Proc. 2016 Nov;48(9):2910-2912. (PMID: 27932105)
Am J Transplant. 2009 Nov;9(11):2520-31. (PMID: 19843030)
Nephrology (Carlton). 2018 Feb;23(2):169-174. (PMID: 27888573)
Transplant Proc. 2009 Jun;41(5):1552-6. (PMID: 19545677)
Am J Transplant. 2012 Oct;12(10):2754-62. (PMID: 22883025)
PLoS One. 2016 Sep 15;11(9):e0162964. (PMID: 27631619)
Curr Opin Pharmacol. 2004 Aug;4(4):347-54. (PMID: 15251127)
Am J Transplant. 2016 Apr;16(4):1266-75. (PMID: 26780484)
BMC Immunol. 2017 Dec 19;18(1):52. (PMID: 29258420)
Transplantation. 2020 Jan;104(1):e16-e22. (PMID: 31609901)
Semin Immunol. 2006 Oct;18(5):305-17. (PMID: 16916610)
Transplantation. 2015 Jan;99(1):21-8. (PMID: 25525921)
Arch Immunol Ther Exp (Warsz). 2016 Dec;64(Suppl 1):47-53. (PMID: 28083608)
Transplantation. 2018 Nov;102(11):1795-1814. (PMID: 30028786)
Transplantation. 2014 May 15;97(9):917-24. (PMID: 24827764)
Front Immunol. 2019 May 15;10:1046. (PMID: 31156628)
Lancet. 2018 Jun 30;391(10140):2619-2630. (PMID: 29910042)
Transpl Immunol. 2017 Dec;45:35-41. (PMID: 28867309)
Mol Immunol. 2005 May;42(7):763-72. (PMID: 15829264)
فهرسة مساهمة: Keywords: ABMR; BAFF; Immunological risk stratification; Kidney transplantation
المشرفين على المادة: 0 (B-Cell Activating Factor)
0 (Biomarkers)
0 (TNFSF13B protein, human)
تواريخ الأحداث: Date Created: 20210810 Date Completed: 20220314 Latest Revision: 20220314
رمز التحديث: 20221213
مُعرف محوري في PubMed: PMC8580904
DOI: 10.1007/s12026-021-09205-4
PMID: 34373996
قاعدة البيانات: MEDLINE
الوصف
تدمد:1559-0755
DOI:10.1007/s12026-021-09205-4